Roivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business Update
Roivant Sciences Ltd. (ROIV)
Company Research
Source: GlobeNewswire
Roivant began trading on Nasdaq under “ROIV”; cash balance increased to $2.5 billion.Dermavant announced final results from the Phase 3 PSOARING 3 long-term extension study of tapinarof in patients with plaque psoriasis (n=763). The study demonstrated 58% of patients who entered the study with a PGA score =2 achieved a PGA score of 0 or 1 and long-term use of tapinarof provided improved and durable effects for up to 52 weeks. 41% of patients in the study achieved complete disease clearance; also observed a median remittive effect of approximately four months for those patients who entered the study with a PGA of 0 after tapinarof treatment. Tapinarof was well tolerated consistent with the previously reported interim analysis.Aruvant released clinical data from third and fourth patients dosed in ongoing Phase 1/2 trial of ARU-1801 in sickle cell disease, showing zero vaso-occlusive events 18 and 12 months after dosing, respectively; to present clinical data at American Society of Hemat
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Arbutus Biopharma jumps after patent victory in fight with Moderna [Seeking Alpha]Seeking Alpha
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $16.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $14.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study [Yahoo! Finance]Yahoo! Finance
ROIV
Earnings
- 2/13/24 - Beat
ROIV
Sec Filings
- 4/12/24 - Form 3
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- ROIV's page on the SEC website